The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA

Cancer Research

Volumn 72, Issue 9, 2012, Pages 2275-2284

  Rabellino, Andrea ^a   Carter, Brandon ^a   Konstantinidou, Georgia ^a   Wu, Shwu Yuan ^b   Rimessi, Alessandro ^a   Byers, Lauren A ^d   Heymach, John V ^d   Girard, Luc ^a,c   Chiang, Cheng Ming ^b   Teruya Feldstein, Julie ^e   Scaglioni, Pier Paolo ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT1; PROTEIN PML RARA; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUMOYLATION;

ANIMALS; ARSENICALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN INHIBITORS OF ACTIVATED STAT; RATS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN;

EID: 84860526509     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3159     Document Type: Article

References (32)

1. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 2007;8:947-56. (Pubitemid 350176509)
2. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, et al. Role of PML in cell growth and the retinoic acid pathway. Science 1998;279:1547-51. (Pubitemid 28217080)
3. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000;406:207-10. (Pubitemid 30469006)
4. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007;8: 1006-16. (Pubitemid 350174636)
5. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006;441:523-7. (Pubitemid 44050155)
6. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 2006;126:269-83. (Pubitemid 44092959)
7. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004;96: 269-79. (Pubitemid 38256272)
8. Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995;10:1315-24.
9. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001;20:7223-33. (Pubitemid 33105011)
10. Scaglioni PP, Pandolfi PP. The theory of APL revisited. Curr Top Microbiol Immunol 2007;313:85-100. (Pubitemid 47400334)
11. Matsushita H, Scaglioni PP, Bhaumik M, Rego EM, Cai LF, Majid SM, et al. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia. J Exp Med 2006;203:821-8.
12. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10:775-83.
13. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001;193:1361-71. (Pubitemid 32565965)
14. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008;10:538-46. (Pubitemid 351627373)
15. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008;10:547-55. (Pubitemid 351627374)
16. Wu SY, Chiang CM. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J 2009;28:1246-59.
17. Nicoletti I, Migliorati G, PagliacciMC, Grignani F, Riccardi C.A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
18. Ding LH, Xie Y, Park S, Xiao G, Story MD. Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology. Nucleic Acids Res 2008;36:e58.
19. Kahyo T, Nishida T, Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell 2001;8:713-8. (Pubitemid 32946947)
20. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ET. Identification of three major sentrinization sites in PML. J Biol Chem 1998;273:26675-82. (Pubitemid 28471682)
21. Galisson F, Mahrouche L, Courcelles M, Bonneil E, Meloche S, Chelbi- Alix MK, et al. A novel proteomics approach to identify SUMOylated proteins and their modification sites in human cells. Mol Cell Proteomics 2011;10:M110 004796.
22. Stehmeier P, Muller S. Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell 2009;33:400-9.
23. Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S, et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 2005;7:143-53. (Pubitemid 40248340)
24. Roussel MJ, Lanotte M. Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene 2001;20:7287-91. (Pubitemid 33105017)
25. Liu B, Tahk S, Yee KM, Fan G, Shuai K. The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science 2010;330:521-5.
26. Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 2005;5:593-605. (Pubitemid 41113191)
27. Schmidt D, Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A 2002;99:2872-7. (Pubitemid 34240553)
28. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009;462:935-9.
29. Yao Q, Li H, Liu BQ, Huang XY, Guo L. SUMOylation-regulated protein phosphorylation: Evidence from quantitative phosphoproteomics analyses. J Biol Chem 2011;286:27342-9.
30. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. The mechanisms of PML-nuclear body formation. Mol Cell 2006;24:331-9. (Pubitemid 44647906)
31. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010;328:240-3.
32. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010;18:88-98.